Facebook
Twitter
LinkedIn
Forward
Less Is More: Reducing Injections and Optimizing Vision With Anti-VEGF Therapy for nAMD, DR, and DME (Online CME Monograph)
Activity Description and Purpose
This educational activity will provide clinicians with insights on the most relevant clinical data for treating wet age-related macular degeneration and diabetic retinopathy/diabetic macular edema. Experts in the field will discuss ways to extend the treatment interval and individualize care in patients who suffer from these sight-threatening diseases. The desired results of this activity are to help clinicians optimize patient care by giving them information that helps them understand the place in therapy of novel and new agents that may decrease treatment burden through extending the treatment interval.
Target Audience
This educational activity is intended for retina specialists and other ophthalmologists.
Learning Objectives
After completing this activity, participants will be better able to:
- Describe the latest clinical data for anti-VEGF treatments for wet age-related macular degeneration
- Describe the latest clinical data for anti-VEGF treatments for diabetic retinopathy/diabetic macular edema
- Individualize care to effectively extend the treatment interval in patients with wet age-related macular degeneration
- Individualize care to effectively extend the treatment interval in patients with diabetic retinopathy/diabetic macular edema
Faculty
 | Katherine Talcott, MD (Chair) Cole Eye Institute Cleveland Clinic Cleveland, Ohio |
 | Zelia M. Correa, MD, PhD
|
 | Jessica Randolph, MD, FASRS Assistant Professor of Ophthalmology Virginia Commonwealth University Richmond, Virginia |
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
Zelia M. Correa, MD, PhD, is a consultant for Castle Biosciences, Inc.
Jessica Randolph, MD, is an advisory board member of AbbVie Inc*, Advarra, and Genentech, Inc*; and is on the speakers bureau for Apellis Pharmaceuticals Inc.
Katherine Talcott, MD, is an advisory board member of Alimera Sciences, Apellis Pharmaceuticals Inc, Bausch & Lomb Incorporated, EyePoint Pharmaceuticals, and Genentech, Inc; is on the speakers bureau for Astellas Pharma Inc, and Genentech, Inc; and is a contracted researcher for Regeneron Pharmaceuticals, Inc, Regenxbio Inc, and Zeiss.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
* The financial relationship existed during the past 24 months but has now ended
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Regeneron Pharmaceuticals, Inc.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Regeneron Pharmaceuticals, Inc.
This CME activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 315
Available Credit
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Participation